Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

Teva wins FDA OK for crucial migraine drug

Teva wins FDA OK for crucial migraine drug 900 before rebates and discounts – exactly the same level as Novartis and Amgen positioned Aimovig, and in line with stablished therapies like Allergan’s Botox. ... other preventive options such as Botox and anti-epilepsy drugs like topiramate

CGRP migraine drugs need prior approval for use, recommends ICER

CGRP migraine drugs need prior approval for use, recommends ICER that it offered value for money, but only if other migraine prevention options such as Allergan’s Botox and anti-epilepsy drugs such as topiramate had been exhausted.

ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line That includes drugs such as Allergan’s Botox, which costs around $3, 500 per year, as well as certain anti-epilepsy drugs such as topiramate.

Novartis, Amgen set low price for first CGRP migraine drug

Novartis, Amgen set low price for first CGRP migraine drug medicines such as the anticonvulsant topiramate or Allergan's Botox. ... As a migraine treatment Botox costs around $3, 500 per year, and analysts predict that the annual price for Aimovig will drop to around $5, 000 with rebates and discounts.

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more Despite this embarrassing failure, yesterday’s Q1 results were encouraging, with revenues up 2.8% thanks to growth in Botox, Vraylar and regenerative medicines.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics